194 related articles for article (PubMed ID: 21831957)
1. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
Clin Cancer Res; 2011 Oct; 17(20):6482-9. PubMed ID: 21831957
[TBL] [Abstract][Full Text] [Related]
2. A Combinatorial Strategy for Targeting
Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
[TBL] [Abstract][Full Text] [Related]
3. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
[TBL] [Abstract][Full Text] [Related]
4. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
6. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
[TBL] [Abstract][Full Text] [Related]
7. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract][Full Text] [Related]
8. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.
Hicks HM; McKenna LR; Espinoza VL; Pozdeyev N; Pike LA; Sams SB; LaBarbera D; Reigan P; Raeburn CD; E Schweppe R
Mol Carcinog; 2021 Mar; 60(3):201-212. PubMed ID: 33595872
[TBL] [Abstract][Full Text] [Related]
11. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
12. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells.
Nanta R; Shrivastava A; Sharma J; Shankar S; Srivastava RK
Mol Cell Biochem; 2019 Apr; 454(1-2):11-23. PubMed ID: 30251117
[TBL] [Abstract][Full Text] [Related]
14. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
Calero R; Morchon E; Martinez-Argudo I; Serrano R
Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Bian P; Hu W; Liu C; Li L
Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
[TBL] [Abstract][Full Text] [Related]
17. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
Sci Rep; 2020 Sep; 10(1):14380. PubMed ID: 32873828
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
Xiao Y; Yu Y; Jiang P; Li Y; Wang C; Zhang R
Cell Oncol (Dordr); 2020 Aug; 43(4):669-680. PubMed ID: 32382996
[TBL] [Abstract][Full Text] [Related]
20. The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis.
Helmy MW; Ghoneim AI; Katary MA; Elmahdy RK
Mol Biol Rep; 2020 Mar; 47(3):2217-2230. PubMed ID: 32088816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]